Novartis Pharma and Sumitomo Dainippon Pharma have entered a copromotion and sales collaboration agreement for the diabetes treatments Equa (vildagliptin) and EquMet (vildagliptin + metformin) in Japan, they said on May 30. Copromotion activities will start on July 1. Through…
To read the full story
Related Article
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





